ASCO study: Use of off-label drugs in breast cancer quite common

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

Researchers from Houston’s M.D. Anderson Cancer Center evaluted the prevalence and impact of off-label therapies in breast cancer and found that nearly 35% of women were treated with off-label chemotherapy at some point during their care.

Researchers from Houston’s M.D. Anderson Cancer Center evaluted the prevalence and impact of off-label therapies in breast cancer and found that nearly 35% of women were treated with off-label chemotherapy at some point during their care.

Sharon Giordano, MD, and colleagues identified 2,082 women (ages 65 and up) diagnosed with metastatic breast cancer between 1991 and 2002 and logged into the SEER database. The DRUGDEX compendium was also referenced (ASCO abstract 1016).

They found that 34.9% of the women were treated with off-label chemotherapy, with the most common off-label chemotherapies noted being vinorelbine tartrate (Navelbine), which is approved for lung cancer, and gemcitabine (Gemzar), which is approved for pancreatic cancer.

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content